Nucleome closes oversubscribed £37.5 million Series A financing

UK-based Nucleome Therapeutics, a spinout from Oxford University founded with the aim to unlock the non-coding regulation of the genome for human health, has closed an oversubscribed £37.5 million ($42.4 million) Series A financing round.

The funds will be used to advance the company's autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The autoimmune diseases market is estimated to be worth in excess of $35 billion.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.